Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level.

Cell death & disease - 5 Nov 2021

Hu Xianjing, Fatima Sarwat, Chen Minting, Huang Tao, Chen Yuen Wa, Gong Ruihong, Wong Hoi Leong Xavier, Yu Rongmin, Song Liyan, Kwan Hiu Yee, Bian Zhaoxiang

Abstract excerpt

Currently, no frontline treatment is effective for the late-stage colorectal cancer (CRC). Understanding the molecular differences in different stages of CRC can help us to identify the critical therapeutic targets for designing therapeutic strategy. Our data show that c-Myc protein is highly expressed in late-stage CRC when compared with early-stage CRC in both clinical samples and in cell lines representing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Artemisinins
Share to Energy Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Ki-67 Antigen

Share to Lipid Metabolism

Share to Luminescent Measurements

Share to Principal Component Analysis

Share to Proto-Oncogene Proteins c-myc

Source

Open in PubMed Open full text

Identifiers

PMID: 34741022
DOI: 10.1038/s41419-021-04247-w
PMCID: PMC8571272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level.PMID 34741022Read ↗

Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic OpportunitiesSemantic proximity Read ↗

Establishment and characterization of 18 human colorectal cancer cell lines.Semantic proximity Read ↗

FTO promotes colorectal cancer progression and chemotherapy resistance via demethylating G6PD/PARP1Semantic proximity Read ↗

High-Dose Vitamin C Tends to Kill Colorectal Cancer with High MALAT1 ExpressionSemantic proximity Read ↗

c-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and DiseaseSemantic proximity Read ↗

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancerSemantic proximity Read ↗

Mitochondria: a crucial factor in the progression and drug resistance of colorectal cancerSemantic proximity Read ↗

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer.Semantic proximity Read ↗

Establishment and characterization of a novel cell line (cc‑006cpm8) of moderately/poorly differentiated colorectal adenocarcinoma derived from a primary tumor of a patient.Semantic proximity Read ↗

Transcriptome Analyses Identify Deregulated MYC in Early Onset Colorectal CancerSemantic proximity Read ↗

CLK3 promotes tumor proliferation by activating MYC signalingSemantic proximity Read ↗

Protein Expression Profiling Identifies Key Proteins and Pathways Involved in Growth Inhibitory Effects Exerted by Guggulsterone in Human Colorectal Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.